Skip Navigation LinksHome > August 2014 - Volume 37 - Issue 4 > Salvage Treatment for Locally Recurrent Nasopharyngeal Carci...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0b013e318277d804
Original Articles: Head and Neck

Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma (NPC)

Chen, Chuangzhen MD*; Fee, Willard MD; Chen, Jianzhou MD*; Chan, Cato BSc; Khong, Brian BA; Hara, Wendy MD; Goffinet, Don MD; Li, Derui MD*; Le, Quynh-Thu MD

Collapse Box

Abstract

Background:

It is important to determine the outcomes of retreatment in patients with locally recurrent nasopharyngeal carcinoma.

Methods:

We reviewed the records of patients treated for local recurrence at Stanford and Shantou Universities. The end points were local relapse-free survival (LRFS) and overall survival after retreatment.

Results:

Fifty-six patients from Stanford and 98 from Shantou qualified. For the Stanford patients, 33 had surgery alone (S group), 12 had surgery plus radiotherapy±chemotherapy (CMT group), and 22 had radiotherapy±chemotherapy (RT Stanford group). All Shantou patients received radiotherapy±chemotherapy (RT Shantou group). The 5-year LRFS rates were: 57% for S group, 25% for CMT group, 53% for RT Stanford group, and 41% for RT Shantou group (P>0.05) for rT1-2 tumors; they were 29% for S group, 25% for CMT group, 39% for RT Stanford group, and 9% for RT Shantou group for rT3-4 tumors (P>0.05). For RT patients, 5-year overall survival rates were 49% for Stanford and 25% for Shantou patients (P=0.026).

Conclusions:

Similar and durable LRFS rates were attained for both S and RT groups when stratified by rT-stage.

Copyright © 2012 by Lippincott Williams & Wilkins

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/AJCOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.

Readers Of this Article Also Read